FATE
Price
$1.00
Change
-$0.03 (-2.91%)
Updated
Sep 3 closing price
Capitalization
115.33M
56 days until earnings call
TRVI
Price
$7.15
Change
-$0.12 (-1.65%)
Updated
Sep 3 closing price
Capitalization
869.49M
62 days until earnings call
Interact to see
Advertisement

FATE vs TRVI

Header iconFATE vs TRVI Comparison
Open Charts FATE vs TRVIBanner chart's image
Fate Therapeutics
Price$1.00
Change-$0.03 (-2.91%)
Volume$1.34M
Capitalization115.33M
Trevi Therapeutics
Price$7.15
Change-$0.12 (-1.65%)
Volume$1.45M
Capitalization869.49M
FATE vs TRVI Comparison Chart in %
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. TRVI commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Buy and TRVI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (FATE: $1.00 vs. TRVI: $7.15)
Brand notoriety: FATE and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 92% vs. TRVI: 78%
Market capitalization -- FATE: $115.33M vs. TRVI: $869.49M
FATE [@Biotechnology] is valued at $115.33M. TRVI’s [@Biotechnology] market capitalization is $869.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, TRVI is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 4 TA indicator(s) are bullish while TRVI’s TA Score has 3 bullish TA indicator(s).

  • FATE’s TA Score: 4 bullish, 4 bearish.
  • TRVI’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than TRVI.

Price Growth

FATE (@Biotechnology) experienced а -10.71% price change this week, while TRVI (@Biotechnology) price change was -10.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.29%. For the same industry, the average monthly price growth was +15.06%, and the average quarterly price growth was +30.89%.

Reported Earning Dates

FATE is expected to report earnings on Oct 30, 2025.

TRVI is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.29% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TRVI($869M) has a higher market cap than FATE($115M). TRVI YTD gains are higher at: 73.544 vs. FATE (-39.394). TRVI has higher annual earnings (EBITDA): -47.19M vs. FATE (-161.6M). FATE has more cash in the bank: 223M vs. TRVI (204M). TRVI has less debt than FATE: TRVI (891K) vs FATE (81.3M). FATE has higher revenues than TRVI: FATE (8.47M) vs TRVI (0).
FATETRVIFATE / TRVI
Capitalization115M869M13%
EBITDA-161.6M-47.19M342%
Gain YTD-39.39473.544-54%
P/E RatioN/AN/A-
Revenue8.47M0-
Total Cash223M204M109%
Total Debt81.3M891K9,125%
FUNDAMENTALS RATINGS
FATE vs TRVI: Fundamental Ratings
FATE
TRVI
OUTLOOK RATING
1..100
6120
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
40
Fair valued
PROFIT vs RISK RATING
1..100
10069
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
8639
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (13) in the Biotechnology industry is in the same range as TRVI (40) in the Pharmaceuticals Major industry. This means that FATE’s stock grew similarly to TRVI’s over the last 12 months.

TRVI's Profit vs Risk Rating (69) in the Pharmaceuticals Major industry is in the same range as FATE (100) in the Biotechnology industry. This means that TRVI’s stock grew similarly to FATE’s over the last 12 months.

TRVI's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as FATE (97) in the Biotechnology industry. This means that TRVI’s stock grew similarly to FATE’s over the last 12 months.

TRVI's Price Growth Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for FATE (86) in the Biotechnology industry. This means that TRVI’s stock grew somewhat faster than FATE’s over the last 12 months.

TRVI's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as FATE (100) in the Biotechnology industry. This means that TRVI’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATETRVI
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 9 days ago
86%
Bullish Trend 3 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRBVX16.700.04
+0.24%
BlackRock Large Cap Focus Value R
PBEAX24.360.02
+0.08%
PGIM Jennison Value A
RIEIX12.920.01
+0.08%
RBC International Equity I
CSJCX66.48-0.19
-0.28%
Cohen & Steers Realty Shares C
FMCVX26.14-0.09
-0.34%
Franklin Mutual Small-Mid Cap Val R6

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-2.91%
RXRX - FATE
53%
Loosely correlated
-0.64%
CRBU - FATE
52%
Loosely correlated
+0.53%
MGNX - FATE
52%
Loosely correlated
+9.77%
ALLO - FATE
51%
Loosely correlated
N/A
NTLA - FATE
50%
Loosely correlated
+2.72%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PTGX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
-1.65%
PTGX - TRVI
43%
Loosely correlated
-1.26%
BIESF - TRVI
43%
Loosely correlated
N/A
GOSS - TRVI
31%
Poorly correlated
-0.39%
XENE - TRVI
28%
Poorly correlated
-1.20%
FATE - TRVI
28%
Poorly correlated
-2.91%
More